The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Adler, L. E.
* Articles by Waldo, M. C.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Adler, L. E.
* Articles by Waldo, M. C.
Related Collections
* Atypical Neuroleptics
* Schizophrenia Spectrum Disorders
Am J Psychiatry 162:386-388, February 2005
© 2005 American Psychiatric Association


Brief Report

Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients

Lawrence E. Adler, M.D., Ellen M. Cawthra, R.N., Kara A. Donovan, M.P.H., Josette G. Harris, Ph.D., Herbert T. Nagamoto, M.D., Ann Olincy, M.D., and Merilyne C. Waldo, Ph.D.

OBJECTIVE: Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the {alpha}-7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential. METHOD: Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug. RESULTS: There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment (ondansetron: mean=41.4%, SD=39.7%; placebo: mean=80.2%, SD=21.3%). CONCLUSIONS: Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics.




This article has been cited by other articles:


Home page
Schizophr BullHome page
D. L. Braff, R. Freedman, N. J. Schork, and I. I. Gottesman
Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder
Schizophr Bull, January 1, 2007; 33(1): 21 - 32.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant, and N. R. Swerdlow
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Schizophr Bull, January 1, 2007; 33(1): 69 - 94.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
D. Potter, A. Summerfelt, J. Gold, and R. W. Buchanan
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Schizophr Bull, October 1, 2006; 32(4): 692 - 700.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org